期刊文献+

妥泰治疗癫痫的长期临床观察

Clinical Observation on the Curative Effects of Topiramate for Epilepsy
暂未订购
导出
摘要 目的观察长期应用妥泰 (TPM)治疗各种类型癫痫的临床疗效、安全性及用药方法.方法采用自身对照方法,对146例各种类型的癫痫患者进行TPM合并用药(81例)和单药(65例)治疗,TPM从小剂量开始,起始量儿童<20kg者为6.25mg/d,≥20kg者为12.5mg/d,成人为25mg/d,根据病情及不良反应,逐渐调整用药剂量.观察时间为1年~3年10个月,平均16.2个月,治疗20周后及1年后与基础期(入组前3个月)月发作频率进行比较.结果合并用药组治疗有效率为80.2%,单药治疗组有效率为87.7%,服药1年以上总有效率为90.4%.不良反应多发生在加量期,其中单药治疗组低于合并用药组,差异有显著性.结论 TPM是一种广谱有效及安全的新型抗癫痫药,可作为一线抗癫痫药,使用过程中应注意个人化原则. Objective To evaluate the clinical efficiency and the reaction of topiramate (TPM) used long - term for various types of epilepsy and the way to administer the drug. Methods 146 cases with epilepsy were randomly assigned to 2 groups: Group A (n = 81) treated with routine antiepileptic combining with topiramate, while Group B treated only with topiramate. The dose of topiramate began with small amount, 6.25mg/d for child under 20 Kg in body weight, 12.5mg/d for child over 20Kg, and 25mg/d for adults. The dose was readapted according the status and untoward reaction respectively. The observation went on 1 year to 3 years and 10 months, average time was 16. 2 months. The frequency of epileptic attack 20 weeks and 1 year after treatment was compared with the frequency of basic stage 3 months before treatment. Results The effective rate was 87.8% and 80,2% in group B and group A respectively. The total average effective rate was 83.6% 1 year after treatment. Side effects often were found in the augmented dose period, and the rate in group B was less than that in group A. The difference between the two groups was significant. Conclusions TPM is a kind of new antiepileptic with the features of broad - spectrum, high performance and secure. The various conditions of different patients should be given more attention.
出处 《实用全科医学》 2005年第6期513-514,共2页 Applied Journal Of General Practice
关键词 妥泰 药物治疗 癫痫 用药剂量 Epilepsy Topiramate Long- term follow- up Observation on curative effect
  • 相关文献

参考文献4

二级参考文献32

  • 1唐章龙,林燕霞,徐雅春,徐志成.405例癫痫的临床分析和8年随访报告[J].临床脑电学杂志,1996,5(4):225-228. 被引量:10
  • 2[1]Biton V.Preliminary open-label experience with topiramate in primary generalized seizures.Epilepsia,1997,38(1):42-48
  • 3[2]Woolf CJ,Mannion RJ.Neuropathic pain:aetiology,Symptoms,mechanism and management.Lancet,1999,353:1959
  • 4[3]Lindberger M,Tomson J,ohman I,et al.Estimation of Topiramate in subdural cerebrospinal fluid,Subcutaneous extracellular fluid,and plasma:a single case microdialysis study.Epilepsia,1999,40:800-802
  • 5[4]Johannessen SI.Pharmacokinetics and interaction profile of topiramate:review and Comparison with other newer antiepileptic drugs.Epilepsia,1997,38(1):18-23
  • 6[5]Reife R,Pledger G,Wu S.Topiramate as addon therapy:Pooled analysis of randomized controlled trials in adults.Epilepsia,2000,41(1):66-71
  • 7[7]Biton V,Montouris GD,Ritter F,et al.A randomized,Placebo-controlled study of topiramate in primary generalized.tonic-clonic seizures.Neurology,1999,52:1330-1337
  • 8[8]Brodie MJ,Biton V,Montouris GD,et al.Topiramate therapy in patients with generalized tonic-clonic seizures without focal onset:long-term outcome.Epilepsia,1998,39(2):2-7
  • 9[9]Reitter FJ,Glauser TA,Sachdeo RC,et al.Long-term experience with topiramate in lennox-Gastaut syndrome.Epilepsia,1998,39(2):2-8
  • 10[10]Guerreiro MM,Manreza ML,Scotoni AE,et al.A Pilot study of topiramate in children With lennox-Gastaut syndrome.Arq Neuropsiquiatr,1999,57(2):167-175

共引文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部